On Monday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) was -8.18% drop from the session before, before settling in for the closing price of $7.95. A 52-week range for DAWN has been $5.64 – $16.76.
Healthcare Sector giant saw their annual sales slid by -38.09% over the last five years. When this article was written, the company’s average yearly earnings per share was at -21.35%. With a float of $74.64 million, this company’s outstanding shares have now reached $102.43 million.
Day One Biopharmaceuticals Inc (DAWN) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Day One Biopharmaceuticals Inc stocks. The insider ownership of Day One Biopharmaceuticals Inc is 27.13%, while institutional ownership is 74.53%. The most recent insider transaction that took place on Aug 18 ’25, was worth 27,786. In this transaction COO and CFO of this company sold 4,106 shares at a rate of $6.77, taking the stock ownership to the 278,000 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Gen Counsel & Secretary sold 4,365 for $6.77, making the entire transaction worth $29,538. This insider now owns 54,858 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 0.38 earnings per share (EPS) during the time that was better than consensus figure (set at -0.25) by 0.63. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 74.86% during the next five years compared to -38.09% drop over the previous five years of trading.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
You can see what Day One Biopharmaceuticals Inc (DAWN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Analysing the last 5-days average volume posted by the [Day One Biopharmaceuticals Inc, DAWN], we can find that recorded value of 2.13 million was better than the volume posted last year of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 71.11%.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 62.95%, which indicates a significant increase from 39.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.36 in the past 14 days, which was higher than the 0.31 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.96, while its 200-day Moving Average is $8.35. Now, the first resistance to watch is $7.78. This is followed by the second major resistance level at $8.27. The third major resistance level sits at $8.52. If the price goes on to break the first support level at $7.04, it is likely to go to the next support level at $6.79. Now, if the price goes above the second support level, the third support stands at $6.30.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are 102,432K outstanding shares of the company, which has a market capitalization of 747.75 million. As of now, sales total 131,160 K while income totals -95,500 K. Its latest quarter income was 33,910 K while its last quarter net income were -30,320 K.
